Suchergebnisse - "PARP inhibitor"

PubPharm (250)

91

BRCA gene testing in women with high-grade serous ovarian carcinoma

enthalten in: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology | 2021

von Kansu, B. | Gardner, J. | Price-Tate, R. | +2

92

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme

enthalten in: Biomolecules | 2021

von Xavier, M. | Rezende, F. | Titze-de-Almeida, R. | +1

93

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer

enthalten in: International journal of molecular sciences | 2021

von Dickson, K. | Xie, T. | Evenhuis, C. | +2

94

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency

enthalten in: Molecular cell | 2021

von Cong, K. | Peng, M. | Kousholt, A. | +13

ErratumIn: Mol Cell. 2021 Aug 5;81(15):3227. - PMID 34358459

95

Precision medicine for hereditary tumors in gynecologic malignancies

enthalten in: The journal of obstetrics and gynaecology research | 2021

von Sekine, M. | Enomoto, T.

96

Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer : The early experience in Taiwan

enthalten in: Taiwanese journal of obstetrics & gynecology | 2021

von Hsu, C. | Pan, Y. | Lai, C. | +3

97

Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells

enthalten in: Cancer research and treatment | 2021

von Cho, H. | Kim, Y. | Park, W. | +1

98

BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer

enthalten in: Future oncology (London, England) | 2021

von Royfman, R. | Whiteley, E. | Noe, O. | +5

99

Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer

enthalten in: Expert review of pharmacoeconomics & outcomes research | 2021

von Cheng, L. | Wong, G. | Chay, W. | +6

100

Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer

enthalten in: Expert opinion on pharmacotherapy | 2021

von Oh, S. | Rahman, S. | Sparano, J.